Table 1. Therapeutic approach related to PDL-1 and Wnt/β-catenin signaling.

Therapy	Target	Out come	References
Nivolumab Pembrolizumab Atezolizumab	PD-1 PDL-1 CTLA-4	Promotion of tumor infiltrating of T CD8+ cells Reinvigorate anti-tumor immunity Improve malignancy trend	[172,173]
Immunecheckpiont inhibitors	PD-1 CTLA-4 Tim-3 TIGIT	Reduction of glycolysis levels in cancerous cells Promotion of glucose in TME and T-cells activation Reduce ability of PD-1 and CTLA-4 receptors Depletion of T-cells and NK cells function	[177] [69] [187]
RNA-interference (RNAi)	Wnt/β-catenin	Increase penetration of cytotoxic T-cells Reduce tumor size Decrease PD-1 inhibitor resistance Tumor cell growth reduction	[178] [115]